We published in @JAMA_current the results of a randomized Phase 2 study of @vedantabio‘s lead candidate VE303 for prevention of recurrent C. difficile infection (rCDI) 👉🧵/1
Consistent large-scale cGMP production of defined bacterial consortia will be critical for late stage clinical studies and commercialization of #microbiome therapies. Today we launched a state-of-the-art manufacturing facility to bridge this gap https://t.co/stQTAjnHQK
Last day at #DDW2022! Had a great time this morning sharing our work to understand why the VE303 higher dose elicits a better clinical response in C. difficile patients.
Recently we published Ph 1 results in healthy volunteers of our defined bacterial consortium VE303 that informed rational dose selection. Today, at #DDW22, we present data showing that VE303 is efficacious in Ph 2 and that higher dose ➡️ better colonization ➡️ higher activity
@VedantaBio at #DDW2022! @ECrossette and I presented data showing successful colonization of consortia strains in healthy and C. Difficile patients, and linking the latter to clinical response.
We are presenting key data on our defined consortia VE303 (C. difficile) and VE202 (IBD) programs at #DDW2022, which is taking place from May 21-23. These include three oral presentations: ...
Recently we published Ph 1 results in healthy volunteers of our defined bacterial consortium VE303 that informed rational dose selection. Today, at #DDW22, we present data showing that VE303 is efficacious in Ph 2 and that higher dose ➡️ better colonization ➡️ higher activity